Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers

HOOKIPA Pharma Inc.

2022-Q3 EPS reported -$0.83 revenue$6,421,000

Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).
Cash $100.7M as of Sep 30, 2022 (up from $66.9M Dec 2021); excludes $25M Roche upfront and up to $30M Gilead stock purchase.
Entered Roche collaboration for HB-700 (KRAS-mutated cancers) and second candidate; $25M upfront, potential $930M milestones plus royalties.
FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer); Phase 1 start expected Q1 2023.
Phase 2 HB-200 + pembrolizumab data expected H1 2023; >20 patients dosed, enrollment ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HOOKIPA Pharma Inc. reported Third Quarter 2022 results: revenue $2.2 million, net income $18.3 million.

Period: Third Quarter 2022
Revenue: $2.2 million
Net income: $18.3 million
Result: reported results

Exact text from the filing

stock that Gilead is required to purchase at the discretion of the Company pursuant to the terms of a stock purchase agreement signed in February 2022 Revenue: Revenue was $2.2 million for the three months ended September 30, 2022, compared to $3.9 million for the three months ended September 30, 2021. The decrease was primarily due to lower cost reimbursements

View on SEC.gov

Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.